MNKD — MannKind Corp
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $2.92
- 30-Day Move
- -49.7%
- Market Cap
- $770M
- Shares Outstanding
- 308,100,000
- P/E Ratio
- 115.01
- P/B Ratio
- 4.03
Analyst consensus: Buy · 15 analysts
MannKind Corp
A read-only Alphactor snapshot forMannKind Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-20
Topline snapshot
Latest Close
$2.92
30-Day Move
-49.7%
Market Cap
$770M
Shares Outstanding
308,100,000
P/E Ratio
115.01
P/B Ratio
4.03
$2.92
-49.7%last 90 delayed daily bars
90D High
$6.51
90D Low
$2.23
Avg Volume
5,135,807
Gross margin is running at 77.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 1.9%, useful for comparing MNKD against peers in Biotechnology.
MNKD is down 49.7% over the last 30 trading days shown on this page.
Latest operating income is $47M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$3.50
Rule of 40
26.2%
Dark Pool Short %
54.1%
Latest Close
$2.92
30-Day Move
-49.7%
Market Cap
$770M
Shares Outstanding
308,100,000
P/E Ratio
115.01
P/B Ratio
4.03
ROE
-349.5%
ROA
74.0%
Gross Margin
77.8%
Operating Margin
11.4%
Net Margin
1.9%
Debt / Equity
1.64
Current Ratio
1.7
Latest Revenue
$349M
Revenue
$349M
Gross Profit
$261M
Operating Income
$47M
Net Income
$6M
Gross Margin
7780.0%
Net Margin
192.0%
Current Ratio
1.70
Debt / Equity
1.64
Fair Value
$3.50
Upside / Downside
+19.9%
Signal
Fairly Valued
Implied Growth
27.2%
DCF
$2.29
EV/Rev
$4.71
Growth Assumption
50.0%
Discount Rate
10.1%
Terminal Growth
2.0%
Base FCF
$14M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
-4.28
Distress
Piotroski
4
Moderate (4-6)
Cash Conversion
3.11x
Rule of 40
26.2%
Acceptable
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $100M | $-69M | $-87M | $-88M |
| 2023-12-31 | $199M | $11M | $-12M | $-8M |
| 2024-12-31 | $286M | $69M | $28M | $33M |
| 2025-12-31 | $349M | $47M | $6M | $14M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$259,000
Sell Value
$4M
Buys
1
Sells
14
Buy Value
$259,000
Sell Value
$4M
Buy/Sell Ratio
0.07x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-23 | Ahuja Ajay | A | 217,000 | $0.00 |
| 2026-03-23 | Ahuja Ajay | A | 221,000 | $0.00 |
| 2026-03-23 | Singh Sanjay R | A | 217,000 | $0.00 |
| 2026-03-23 | Singh Sanjay R | A | 221,000 | $0.00 |
| 2026-03-23 | Prentiss Christopher B | A | 217,000 | $0.00 |
| 2026-03-23 | Prentiss Christopher B | A | 221,000 | $0.00 |
| 2026-03-23 | Castagna Michael | A | 782,000 | $0.00 |
| 2026-03-23 | Castagna Michael | A | 796,000 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 11,441,149 | 0.04% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 9,147,582 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 7,352,050 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 3,299,258 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2,925,397 | 0.01% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 2,526,680 | 0.01% | 2026-02-28 |
| iShares Trust-iShares Biotechnology ETF | 2,224,377 | 0.01% | 2026-02-28 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2,185,101 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
BlackRock
Filed 2024-08-13
$118M
--
Vanguard Group
Filed 2026-01-29
$101M
+1.4%
Geode Capital Management
Filed 2026-02-09
$42M
-0.2%
FMR LLC (Fidelity)
Filed 2026-02-17
$20M
+7.8%
Citadel Advisors
Filed 2026-02-17
$20M
--
Two Sigma Advisers
Filed 2025-05-15
$19M
+20.8%
4.2
Consensus
Buy—
—
—
15
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.